DBVT News and Press, DBV Technologies S.A. From 03/01/19

Montrouge, France, March 1, 2019 DBV Technologies to Attend Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that members of its management team w...

Montrouge, France, February 22, 2019 DBV Technologies Announces Publication of Detailed Phase III Trial Results Evaluating Viaskin Peanut as a Novel Treatment for Peanut Allergy in The Journal of the American Medical Association Viaskin Peanut is the first epicutaneous immunother...

Stamps.com (NASDAQ: STMP )  -52%  on Q4 earnings . More news on: Stamps.com Inc., GTx, Inc., The Kraft Heinz Company, Stocks on the move, Read more ...

Kandi Technologies (NASDAQ: KNDI ) +28%  as NHTSA approves two pure electric vehicle models. More news on: Kandi Technologies Group, Inc., BioSig Technologies, Inc., OneSpan Inc, Stocks on the move, Read more ...

Reebonz Holding ( RBZ ) +76% . More news on: Reebonz Holding Ltd. Class A, Invacare Corporation, Electrameccanica Vehicles Corp. Ltd., Stocks on the move, Read more ...

Gainers: IVC   +19.3% . DBVT   +19.1% . SNBR   +11.1% . YELP   +6.3% . VNDA   +5.0% . More news on: Presidio, Invacare Corporation, DBV Technologies, , Stocks on the move, News on ETFs, Read more ...

Montrouge, France, February 13, 2019 DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children 4 to 11 Years of Age Progress made to date to enable BLA resubmission in Q3 2019 Company to hold conference call today, Febr...

                                                                                  &#x...

Aimmune ( AIMT ) suffered a setback and through no fault of its own. It was notified by the FDA that its Biologics Licensing Application ((BLA)) would not be reviewed because of the government shutdown. The stock fell about 5% on Monday after the release of the news, and then slightly ag...

DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019 Novel immunotherapy based on Viaskin technology highlighted as a potential treatment for food-allergic patients DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinic...